Unlock instant, AI-driven research and patent intelligence for your innovation.
Heterocyclic compound as well as preparation method and medical application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of compound and heterocyclic group, applied in the field of heterocyclic compound, its preparation and its application in medicine, can solve problems such as difficulties
Inactive Publication Date: 2020-12-29
GUANGZHOU INNOCARE PHARMA TECH CO LTD
View PDF6 Cites 2 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, due to the high sequence similarity of the active sites of the JAK kinase family, it is quite difficult to develop a selective JAK inhibitor
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0137] p-Toluenesulfonamide (17.12g, 100mmol), anhydrouspotassiumcarbonate (27.6g, 200mmol) and anhydrousacetonitrile (200mL) were mixed, then 3-chloro-2-chloromethyl-1- Propylene 1a (12.5 g, 100 mmol) in acetonitrile (20 mL). After the mixture was stirred under reflux for 18 hours, it was cooled to room temperature, and water (250 mL) was added, followed by stirring for 30 minutes. The precipitate was collected by filtration to obtain 20 g of crude product. The crude product was purified by silica gelcolumn chromatography (petroleumether / dichloromethane=100 / 0 to 0 / 100) to obtain the target product (10.8 g, solid), yield: 48%.
[0138] MS m / z(ESI):447[M+1]
[0139] 1 H NMR (400MHz, CDCl 3 )δ7.70-7.64(m,4H),7.31(d,J...
[0169] To a 10-mL microwave reaction vial, add (3aR,6aS)-5-(2-chloropyrimidin-4-yl)-3a,6a-dimethylhexahydropyrrolo[3,4-c]pyrrole-2- (1H)-tert-butylcarboxylate 1e (100mg, 0.283mmol), tert-butyl 4-aminobenzoate (55mg, 0.283mmol), p-toluenesulfonic acid (5mg, 0.0283mmol) and isopropanol (4mL ), then the mixture was stirred at 100 °C for 1 h in a microwave reactor. After cooling to room temperature, the solvent was removed under reduced pressure, and the residue was purified by silica gelcolumn chromatography (petroleumether / ethyl acetate=2 / 1 to 1 / 2) to obtain the target product (3aR, 6aS)-5-(2-( (4-(tert-butoxycarbonyl)phenyl)amino)pyrimidin-4-yl)-3a,6a-d...
[0183]4-((4-((3aR,6aS)-5-(cyclopropylcarbonyl)-3a,6a-dimethylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidine -2-yl)amino)benzoic acid 2 (56mg, 0.133mmol) was dissolved in dichloromethane (10mL), then diisopropylethylamine (59mg, 0.153mmol) and 2-(7-oxybenzo Triazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (58 mg, 0.153 mmol). After stirring at room temperature for 5 minutes, 3 drops of aqueous ethylamine (65%-70%wt) were added. The mixture was stirred at room temperature for 30 minutes, then the solvent was removed under reduced pressure, and the residue was purified by reverse-phase preparative liquid chromatography to obtain the target product 4-((4-((3aR,6aS)-5-( Cyclopropylcarbonyl)-3a,6a-dimethylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-2-yl)amino)-N-ethylbenzamide 3(3.3 mg, solid), yield: 6%.
...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention relates to a heterocyclic compound suitable for inhibiting or regulating Janus family kinase (JAK), in particular tyrosinekinase 2 (TYK2), a preparation method of the heterocyclic compound and application of the heterocyclic compound in medicine. Specifically, the present invention relates to a compound represented by a general formula (I), a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof, and a method of using the compound or the pharmaceutically acceptable salt thereof to treat and / or prevent Janus kinase-mediated related diseases, especially autoimmune diseases, inflammatory diseases and cancers and a method for preparing the compound or pharmaceutically acceptable salt thereof. The invention also relates to application of the compound or the pharmaceutically acceptable salt thereof or the pharmaceutical composition containing the compound or the pharmaceutically acceptablesalt thereof in preparation of drugs for treating and / or preventing Janus kinase mediated related diseases, especially autoimmune diseases, inflammatory diseases and cancers. Each substituent of thegeneral formula (I) is as defined in the specification.
Description
technical field [0001] The present invention relates to a novel heterocyclic compound or a pharmaceutically acceptable salt thereof for regulating or inhibiting the activity of Janus kinase (JAK), especially tyrosinekinase 2 (TYK2), containing the compound or its pharmaceutically acceptable The pharmaceutical composition of the salt, the preparation method of the compound or its pharmaceutically acceptable salt and the pharmaceutical composition of the compound or its pharmaceutically acceptable salt or containing the compound or its pharmaceutically acceptable salt are used in the preparation Use in medicines for treating and / or preventing related diseases mediated by the kinase, especially autoimmune diseases, inflammatory diseases and cancers, and methods of use thereof. Background technique [0002] Janus kinase (JAK) is a non-receptortyrosineprotein kinase consisting of four family members, namely JAK1, JAK2, JAK3 and TYK2. JAK has 7 homologous domains (JAK Homology...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More